Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Applied Therapeutics ( (APLT) ) has issued an announcement.
On February 7, 2025, Applied Therapeutics received a notification from Nasdaq indicating that its common stock had been trading below the minimum bid price required for continued listing on the Nasdaq Global Market. The company was given until August 6, 2025, to regain compliance. To address this, Applied Therapeutics has applied to transfer its listing to the Nasdaq Capital Market, which could grant an additional 180-day remediation period if approved. However, Nasdaq has not yet granted the application, and there is no assurance that the stock will not be delisted.
The most recent analyst rating on (APLT) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.
Spark’s Take on APLT Stock
According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.
Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.
To see Spark’s full report on APLT stock, click here.
More about Applied Therapeutics
Average Trading Volume: 2,083,774
Technical Sentiment Signal: Sell
Current Market Cap: $63.58M
See more insights into APLT stock on TipRanks’ Stock Analysis page.